Key result
Minimally invasive mitral valve surgery in re-do cases shows 0% in-hospital mortality.
Why the study?
In re-do mitral valve cases, right mini-thoracotomy offers a potential advantage over re-sternotomy through a previously non-operated situs, though minimally invasive mitral valve surgery is a more challenging procedure.
Is minimally invasive mitral valve surgery safe and feasible in cardiac re-do operations?
Observational (n=33)
No
Is minimally invasive mitral valve surgery safe and feasible in cardiac re-do operations?
Minimally invasive mitral valve surgery in re-do cases can be performed with 0% in-hospital mortality and acceptable morbidity, offering a safe alternative to re-sternotomy.
May support feasibility in selected re-do cases; leaves open need for larger comparative trials before practice change.
Background Minimally invasive mitral valve surgery (MIMVS) is superior to “classical” mitral valve surgery via a sternotomy regarding wound healing and postoperative pain. It is however a more challenging procedure. Patients' preference is leading clearly toward minimally invasive approaches, and surgeons are driven by upcoming new technologies in interventional procedures such as the MitraClip. Especially in re-do cases, the access via right mini-thoracotomy, as previously non-operated situs, is a possible advantage over a re-sternotomy. We therefore retrospectively analyzed our result regarding MIMVS in re-do cases at our institute. Methods From January 2011 and June 2016, 33 operations were MIMVS re-do procedures. Mean age was 60 years (±16 years), and 51% were male. Results Sixty-one percent were elective cases, 29% were urgent cases, and 9% were emergency operations. Operation times, cardiopulmonary bypass (CPB) times, and clamp times were 235 minutes (±51 min), 149 minutes (±42 min), and 62 minutes (±45min), respectively. Mitral valve repair and replacement was performed in 24% (n = 8) and 76% (n = 25), respectively. Overall in-hospital mortality, apoplexy, and re-operation rates (all for bleeding) were 0% (n = 0), 3% (n = 1), and 9% (n = 3). New onset of dialysis was required in two (6%) patients. Two (6%) patients developed superficial wound infection. Overall intensive care unit (ICU) and hospital stay was 3 days (±4 days) and 15 days (±7 days), respectively. Conclusion MIMVS for re-do cases can be performed with minimal mortality and morbidity and therefore represents a safe alternative to conventional mitral valve surgery in cardiac re-do operations. However, postoperative morbidity is highly dependent on preoperative patient status.
No takes yet. Share an insight, caveat, or question.
Salman et al. (2018) conducted an observational in Re-do mitral valve surgery (n=33). Minimally invasive mitral valve surgery (MIMVS) was evaluated on In-hospital mortality. Minimally invasive mitral valve surgery in 33 re-do cases demonstrated 0% in-hospital mortality, 3% apoplexy, and 9% re-operation rates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: